# Hospital Universitario Virgen Macarena

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/hospital-universitario-virgen-macarena/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 76.5 |
| Citations | 467,691 |
| City | Seville |
| Country | ES |
| Description | Hospital Universitario Virgen Macarena is a research organisation in Seville, ES. OpenAlex records 10,951 works and 467,691 citations for it. 4,128 researchers list it as their most recent affiliation. |
| Homepage | http://www.hospital-macarena.com/es/especialidades |
| OpenAlex ID | https://openalex.org/I4210090436 |
| Researchers | 4,128 |
| ROR ID | https://ror.org/016p83279 |
| Type | healthcare |
| Works | 10,951 |

## University papers

Showing 12 of 22.

- [Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis](https://scholariq.org/papers/discovery-research-and-development-of-new-antibiotics-the-who-priority-list-of/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [The global threat of antimicrobial resistance: science for intervention](https://scholariq.org/papers/the-global-threat-of-antimicrobial-resistance-science-for-intervention/)
- [European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)](https://scholariq.org/papers/european-society-of-clinical-microbiology-and-infectious-diseases-escmid/)
- [ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients](https://scholariq.org/papers/escmid-guidelines-for-the-management-of-the-infection-control-measures-to-reduce/)
- [Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae](https://scholariq.org/papers/treatment-of-infections-caused-by-extended-spectrum-beta-lactamase-ampc-and/)
- [A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407](https://scholariq.org/papers/a-randomized-placebo-controlled-trial-of-pembrolizumab-plus-chemotherapy-in/)
- [Global dissemination of a multidrug resistant <i>Escherichia coli</i> clone](https://scholariq.org/papers/global-dissemination-of-a-multidrug-resistant-i-escherichia-coli-i-clone/)
- [Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-squamous-non-small-cell-lung-cancer-5-year/)
- [Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study](https://scholariq.org/papers/effect-of-appropriate-combination-therapy-on-mortality-of-patients-with/)
- [Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial](https://scholariq.org/papers/four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-an/)
- [A Multinational Survey of Risk Factors for Infection with Extended‐Spectrum β‐Lactamase–Producing Enterobacteriaceae in Nonhospitalized Patients](https://scholariq.org/papers/a-multinational-survey-of-risk-factors-for-infection-with-extended-spectrum/)

## University researchers

- [Jesús Rodríguez‐Baño](https://scholariq.org/researchers/jesus-rodriguez-bano/)

## University top topics

Showing 8 of 25.

- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Antibiotic Use and Resistance](https://scholariq.org/topics/antibiotic-use-and-resistance/)
- [Antibiotics Pharmacokinetics and Efficacy](https://scholariq.org/topics/antibiotics-pharmacokinetics-and-efficacy/)
- [Bacterial Identification and Susceptibility Testing](https://scholariq.org/topics/bacterial-identification-and-susceptibility-testing/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Nosocomial Infections in ICU](https://scholariq.org/topics/nosocomial-infections-in-icu/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.